Make a positive diagnosis from the pain-stool pattern, then test only what can change it.
Primary diagnostic imageIBS is a disorder of gut-brain interaction without a structural lesion, so anatomy stays normal while function and sensation change.National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health / NIDDK, NIH (Public domain). SourcePublic domain
Apply Rome IV symptom timing and classify IBS-C, IBS-D, IBS-M, or IBS-U with Bristol stool form.
Identify alarm features and choose limited testing that distinguishes celiac disease or inflammatory disease when appropriate.
Treat IBS as a disorder of gut-brain interaction with diet, lifestyle, behavioral therapy, and subtype-directed medication.
Key distinctions
Separate the closest diagnoses
The figure compares the nearest alternatives and highlights the finding that separates them.
Quick check
Rome IV makes abdominal pain central and links it to defecation or a change in stool pattern.
Which symptom pattern meets the core frequency and timing requirement?
Reason it through
What symptom is required?Recurrent abdominal pain.
What associations count?Relation to defecation, change in stool frequency, or change in stool form; at least two are required.
When must symptoms have begun?At least 6 months before diagnosis.
No recurrent pain means no Rome IV IBS.
Separate gut-brain interaction from inflammation
IBS can be disabling without causing ulcers, fistulas, bleeding, or progressive tissue injury.
Visceral hypersensitivity, altered motility, microbiota, immune signaling, diet, and central processing can all contribute to symptoms.
A normal fecal calprotectin in a low-risk IBS-D presentation makes active IBD less likely; persistent bleeding, anemia, weight loss, or objective inflammation demands another path.
Choose the feature that most strongly redirects away from uncomplicated IBS.
Choose the first item.
Classify the stool pattern
Subtype is based on stool form on abnormal bowel-movement days, not every stool ever passed.
Use the Bristol Stool Form Scale: types 1 to 2 are hard, types 6 to 7 are loose, and types 3 to 5 are not counted toward subtype thresholds.
Subtype can change over time, so reassess when the dominant bowel pattern changes.
Compare the Rome IV subtypes.
More than 25% of abnormal stools are Bristol 1 to 2 and fewer than 25% are Bristol 6 to 7.
More than 25% are Bristol 6 to 7 and fewer than 25% are Bristol 1 to 2.
More than 25% are Bristol 1 to 2 and more than 25% are Bristol 6 to 7.
Rome IV IBS is present, but stool-form proportions do not meet C, D, or mixed thresholds.
Keep the thresholds straight
Rome IV and Bristol thresholds standardize the diagnosis without replacing clinical judgment.
Pain occurs on average at least 1 day per week during the last 3 months.
At least two of three associations are required: relation to defecation, change in stool frequency, and change in stool form.
Subtype thresholds use more than 25% of abnormal bowel movements, and symptoms must have begun at least 6 months before diagnosis.
Place each threshold on the Rome IV scale.
Required associated features out of three
Assessment window in months
Minimum onset before diagnosis in months
Subtype threshold percentage
Commit before the explanation appears.
Map therapies to the dominant symptom
One therapy rarely treats pain, bloating, constipation, and diarrhea equally.
Start with a clear explanation, regular meals, exercise, sleep support, and soluble fiber such as psyllium; insoluble wheat bran can worsen bloating.
A limited low-FODMAP trial is best delivered with dietitian support and followed by structured reintroduction to avoid unnecessary restriction.
Gut-directed psychotherapy treats central amplification and coping without implying that symptoms are imaginary.
Place each therapy on its target.
Consider a low-dose tricyclic antidepressant, especially when diarrhea coexists; titrate for neuromodulation rather than mood.
Secretagogues such as linaclotide, plecanatide, or lubiprostone can improve bowel and global symptoms; tenapanor is another option.
Rifaximin can improve global IBS-D symptoms; loperamide slows stool but has limited evidence for global pain.
Use a time-limited low-FODMAP trial with reintroduction, or soluble fiber when tolerated.
Use gut-directed cognitive behavioral therapy or hypnotherapy as active treatment.
Make a positive diagnosis with limited testing
A careful history should determine whether testing changes the probability of a mimic.
Confirm the Rome IV pain-stool relationship, subtype, duration, medication exposures, diet, family history, and psychosocial amplifiers.
Look for bleeding, iron-deficiency anemia, unintentional weight loss, fever, nocturnal diarrhea, palpable mass, older new onset, and family history of colorectal cancer, IBD, or celiac disease.
In suspected IBS-D without alarm features, check celiac serology and use CRP and fecal calprotectin to help exclude IBD; avoid routine colonoscopy in younger patients without warning signs.
Order the diagnostic sequence.
Establish recurrent pain plus at least two defecation or stool-change associations.
Any warning sign redirects the workup toward structural, inflammatory, neoplastic, or malabsorptive disease.
Celiac serology and inflammatory markers are most useful in diarrhea-predominant presentations.
When criteria fit and red flags are absent, explain the diagnosis rather than saying every test is normal.
Limited testing is precise testing, not no testing.
Disclose the tradeoffs before prescribing
Subtype-directed treatment works best when contraindications and symptom targets are explicit.
Eluxadoline can reduce IBS-D symptoms but is contraindicated without a gallbladder and in patients at increased pancreatitis risk.
Polyethylene glycol improves stool frequency in chronic constipation but has limited evidence for global IBS-C pain, so add or choose a therapy that treats the patient's actual target.
Alosetron is restricted to selected women with severe refractory IBS-D because ischemic colitis and serious constipation are uncommon but important harms.
Reveal the decision-changing detail.
Avoid eluxadoline because pancreatitis risk is increased.
A low-dose TCA can address pain and slow transit; monitor anticholinergic effects.
Avoid a constipating neuromodulator when possible and select an IBS-C agent that improves global symptoms.
Confirm celiac disease appropriately before labeling symptoms as IBS-D.
Investigate intestinal inflammation rather than escalating IBS therapy.
Decisive finding
Pick the discriminator
Choose the finding that separates the closest competing diagnoses.
Which symptom pattern meets the core frequency and timing requirement?
Key finding. Rome IV makes abdominal pain central and links it to defecation or a change in stool pattern.
Answer. Abdominal pain at least 1 day per week in the last 3 months, with symptom onset at least 6 months before diagnosis
Why. This states the Rome IV frequency and chronicity requirements.
Board rule. No recurrent pain means no Rome IV IBS.
Stage 1 of 3: Overview
Overview
Irritable Bowel Syndrome
A careful history should determine whether testing changes the probability of a mimic.
Step by step
Make a positive diagnosis with limited testing
1Confirm Rome IVEstablish recurrent pain plus at least two defecation or stool-change associations.
2Check alarm featuresAny warning sign redirects the workup toward structural, inflammatory, neoplastic, or malabsorptive disease.
3Use subtype-specific testsCeliac serology and inflammatory markers are most useful in diarrhea-predominant presentations.
4Name IBS positivelyWhen criteria fit and red flags are absent, explain the diagnosis rather than saying every test is normal.
Clinical takeaway
Why it mattersLimited testing is precise testing, not no testing.
RememberNo recurrent pain means no Rome IV IBS.
Separate the competing diagnoses
Five patients test Rome IV timing, alarm features, subtype arithmetic, inflammatory mimics, and treatment contraindications.
Cross out mimics and highlight the finding that separates the diagnoses. Shuffle to compare a new case order.
A 28-year-old has abdominal pain two days weekly for nine months. Pain often improves after defecation and began when stools became looser and more frequent. There is no bleeding, weight loss, fever, or anemia.
Which diagnosis is best supported?
Reason it through
How often is pain required?At least 1 day per week on average.
How many associations are present?Relation to defecation plus changes in frequency and form.
Is chronicity adequate?Yes. Symptoms began more than 6 months ago and were active during the last 3 months.
Count pain, associations, and time before ordering a fishing expedition.
How often is pain required?How many associations are present?
How often is pain required?At least 1 day per week on average.
How many associations are present?Relation to defecation plus changes in frequency and form.
Is chronicity adequate?Yes. Symptoms began more than 6 months ago and were active during the last 3 months.
A 34-year-old meeting Rome IV criteria reports that 40% of abnormal stools are Bristol type 1 or 2 and 35% are type 6 or 7.
Which subtype applies?
Reason it through
Do normal-form stools enter the denominator?Subtype classification focuses on abnormal bowel-movement days.
Does the hard-stool percentage cross 25%?Yes.
Does the loose-stool percentage cross 25%?Yes, making the subtype mixed.
Both sides over 25% means mixed.
Do normal-form stools enter the denominator?Does the hard-stool percentage cross 25%?
Do normal-form stools enter the denominator?Subtype classification focuses on abnormal bowel-movement days.
Does the hard-stool percentage cross 25%?Yes.
Does the loose-stool percentage cross 25%?Yes, making the subtype mixed.
A 52-year-old labeled with IBS-D now has nocturnal diarrhea, a 7-kg unintentional weight loss, and hemoglobin of 9.8 g/dL.
What is the most appropriate next step?
Reason it through
Which finding is objective?Anemia.
Which timing is atypical for IBS?Diarrhea that wakes the patient at night.
What broad categories must be reconsidered?Inflammatory, neoplastic, malabsorptive, infectious, and medication-related disease.
A prior IBS label does not immunize a patient against new disease.
Which finding is objective?Which timing is atypical for IBS?
Which finding is objective?Anemia.
Which timing is atypical for IBS?Diarrhea that wakes the patient at night.
What broad categories must be reconsidered?Inflammatory, neoplastic, malabsorptive, infectious, and medication-related disease.
A 30-year-old has pain and loose stools but no alarm features. Celiac serology is negative, CRP is normal, and fecal calprotectin is low.
Which conclusion is most appropriate?
Reason it through
Why check celiac serology?Celiac disease can mimic IBS-D and has specific treatment.
What do CRP and calprotectin contribute?They reduce the likelihood of active inflammatory bowel disease in a low-risk presentation.
What makes this a positive diagnosis?The Rome IV pattern plus absence of warning features and focused exclusion of plausible mimics.
IBS is diagnosed from a coherent pattern, not from exhaustion.
Why check celiac serology?What do CRP and calprotectin contribute?
Why check celiac serology?Celiac disease can mimic IBS-D and has specific treatment.
What do CRP and calprotectin contribute?They reduce the likelihood of active inflammatory bowel disease in a low-risk presentation.
What makes this a positive diagnosis?The Rome IV pattern plus absence of warning features and focused exclusion of plausible mimics.
A 46-year-old with IBS-D and no gallbladder asks about eluxadoline after loperamide improved stool frequency but not pain.
Which treatment choice is best supported?
Reason it through
What changed the drug choice immediately?Absence of a gallbladder.
What symptom remains untreated?Abdominal pain.
Which alternatives can target global IBS-D symptoms?Rifaximin or a carefully titrated low-dose TCA, selected for patient-specific risks.
Contraindications outrank the attractiveness of a drug mechanism.
What changed the drug choice immediately?What symptom remains untreated?
What changed the drug choice immediately?Absence of a gallbladder.
What symptom remains untreated?Abdominal pain.
Which alternatives can target global IBS-D symptoms?Rifaximin or a carefully titrated low-dose TCA, selected for patient-specific risks.
Rapid review
Three questions to check
Which symptom pattern meets the core frequency and timing requirement?
Abdominal pain at least 1 day per week in the last 3 months, with symptom onset at least 6 months before diagnosis. This states the Rome IV frequency and chronicity requirements.
How often is pain required?
At least 1 day per week on average.
How many associations are present?
Relation to defecation plus changes in frequency and form.
Resident physician and founding medical reviewer at Bone Wizardry, focused on clinical accuracy, clear diagnostic reasoning, and practical board-oriented teaching across the curriculum.
